Prazosin for Treatment With PTSD And Comorbid Alcohol Dependence
Abstract
There is a high rate of comorbidity with alcohol dependence (AD) and post traumatic stress disorder (PTSD). The rates of PTSD among individuals with AD are at least twice as high as those in the general population. In addition, alcohol dependence is the most common comorbid condition in men with PTSD. Despite this, little is known about how to best treat individuals with comorbid AD and PTSD. The use of an alpha-1 adrenergic receptor antagonist represents a novel approach to treatment that may target symptoms of both AD and PTSD. There is evidence of common neurobiological mechanism that underly both AD and PTSD. Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosis (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD. One hundred and twenty participants with the current diagnosis of AD and PTSD will be enrolled in a 13 week trial, They will be assigned, in a double-blind fashion, to either prazosin or placebo as effective treatments for reducing alcohol consumption and PTSD symptoms in patients with both AD and PTSD.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2010
- Accession Number
- ADA540933
Entities
People
- Ismene Petrakis
Organizations
- Yale University